Analytical Data
-
Gene name
TPD52
- Application
-
Alternative Names
Protein N8
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P55327
-
Expression Region
1-184aa
-
Molecular Weight
35.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TPD52 (Tumor Protein D52) is a member of the TPD protein family that has garnered significant interest in cancer research due to its upregulation in various malignancies. Initially identified as a protein associated with tumor formation, TPD52 has been implicated in critical cellular processes such as cell proliferation, apoptosis, and migration. Studies have shown that TPD52 is overexpressed in several cancer types, including breast, prostate, and lung cancers, suggesting a potential role as a biomarker for tumor progression. The mechanism of action of TPD52 appears to involve the modulation of signaling pathways related to growth factors and oncogenes, possibly influencing the transcriptional regulation of genes involved in cancer development. Researchers have been particularly focused on understanding the structural and functional properties of TPD52 to explore its potential as a therapeutic target. By investigating the underlying molecular interactions and pathways that TPD52 participates in, scientists aim to develop innovative strategies for cancer treatment and early detection. Furthermore, the study of TPD52 has implications beyond oncology, as it may also contribute to our understanding of cellular differentiation and neurobiology. Overall, the research surrounding TPD52 is crucial for elucidating its role in tumorigenesis and developing targeted therapies that could improve clinical outcomes for cancer patients.
